Trial Profile
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Lurasidone (Primary) ; Quetiapine
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Acronyms PEARL-3
- Sponsors Sunovion Pharmaceuticals
- 09 Nov 2021 Results of pooled analysis evaluating novelty of a safety profile of a drug in a new class (in clinical trials), against that of those already on the market (using pharmacovigilance data) published in the Clinical Drug Investigation
- 09 Oct 2018 Results assessing the potential influence of inflammation, obesity and lipid metabolism on changes in cognitive performance and symptom severity, presented at the 31st Annual Congress of the European College of Neuropsychopharmacology
- 20 Sep 2016 Results of pooled, post hoc analysis of this and other four trials presented at the 29th Annual Congress of the European College of Neuropsychopharmacology.